Course InformationTherapautic Area: Neurology
Credit(s): 1.00 AMA PRA Category 1 Credit(s)™
Activity Dates: March 24, 2017 to March 23, 2018
This enduring CME webcast was derived from content presented at a live symposium at the ACTRIMS Forum 2017 held in Orlando, Florida. Five expert faculty will discuss sphingosine-1-phosphate science, and provide an update on selective S1P receptor modulators. Practical assessment of benefits versus risk, including infectious disease risk, in patients treated with S1P therapeutics, will be reviewed. Faculty will relay best practices for shared decision making through patient education as well as strategies for engagement of the multidisciplinary team. Upon completion of this educational activity, learners will gain better insight into the emerging role of S1P-based therapeutics in the management of patients with multiple sclerosis.
Neurologists, and other healthcare professionals who care for patients with MS.
- Understand the science of selective sphingosine-1-phosphate therapeutics.
- Analyze current and emerging clinical trial data for selective S1P-based therapeutics for the management of patients with MS.
- Evaluate the benefit vs. risk balance for pharmacotherapeutic options to treat patients with MS.
Disclosures of Conflict of Interest
It is the policy of AcademicCME that all faculty, instructors, and planners disclose real or apparent conflicts of interest relating to the topics of this educational activity.
The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:
|Faculty||Relationship Identified With:|
|Fred D. Lublin, MD||Consultant/Advisor: AbbVie Inc.; Actelion Pharmaceuticals; Acorda Therapeutics; Akros Pharma Inc.; Amgen Inc.; Atara Biotherapeutics; Bayer AG; Biogen; Celgene Corporation; EMD Serono, Inc.; Forward Pharma; Genentech, Inc.; Genzyme Corporation; Mapi-Pharma Ltd.; Medday; MedImmune; POLYPHARMA; Novartis Pharmaceuticals Corporation; sanofi-aventis U.S. LLC; Roche; Teva Pharmaceutical Industries Ltd.; TG Therapeutics, Inc.; ToyamaGrant/Research Support: Biogen; Celgene Corporation; Genzyme Corporation; Novartis Pharmaceuticals Corporation; sanofi-aventis U.S. LLC; Teva Pharmaceutical Industries Ltd.; Transparency Life SciencesSpeaker’s Bureau: Genentech, Inc.; Genzyme Corporation|
|Jack Antel, MD||Grant/Research Support: Novartis Pharmaceuticals Corporation|
|Joseph R. Berger, MD||Consultant/Advisor: Amgen Inc.; AstraZeneca; Bayer AG; Biogen; Eisai Co., Ltd.; Forward Pharma; Genentech, Inc.; Genzyme Corporation; Incyte Corporation; Inhibikase Therapeutics, Inc.; Janssen Global Services, LLC; Johnson & Johnson Services, Inc; Novartis Pharmaceuticals Corporation; PAREXEL International Corporation; Pfizer Inc.; Roche; Takeda Pharmaceuticals U.S.A., Inc.Grant/Research Support: Biogen; Teva Pharmaceutical Industries Ltd.|
|Mark S. Freedman, MD||Consultant/Advisor: Actelion Pharmaceuticals; Bayer AG; Biogen; Chugai Pharmaceutical Co., Ltd.; EMD Serono, Inc.; Genzyme Corporation; MedDay; Merck & Co.; Novartis Pharmaceuticals Corporation; Roche; sanofi-aventis U.S. LLC; Teva Canada InnovationGrant/Research Support: Genzyme CorporationSpeaker’s Bureau: Genzyme Corporation|
|Amy Perrin Ross, APN, MSN, CNRN, MSCN||Consultant/Advisor: Acorda Therapeutics; Bayer AG; Genentech, Inc.; Genzyme Corporation; Roche; Teva Pharmaceutical Industries Ltd.Speaker’s Bureau: Acorda Therapeutics; Biogen; EMD Serono, Inc.; Genzyme Corporation; Mallinckrodt Pharmaceuticals; Novartis Pharmaceuticals Corporation; Teva Pharmaceutical Industries Ltd.|
Planners, Managers, Reviewers
Timothy Hayes, MD, PhD; Emma Gilmartin and Nicole Brestowski hereby state that they or their spouse/life partner do not have any financial relationships to products or devices with any commercial interests related to the content of this activity of any amount during the past 12 months.
AcademicCME is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Credit Designation Statement
AcademicCME designates this enduring material for a maximum of 1.00 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This activity has been supported by an independent educational grant from Celgene Corporation.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. AcademicCME and Celgene Corporation do not recommend the use of any agent outside of the labeled indications.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Method of Participation
In order to claim credit, participants must complete the following:
- Read the learning objectives, accreditation information and faculty disclosures at the beginning of this activity.
- Complete the Pre-Activity Questions
- Read or Review the activity content.
- Complete the Post-Activity Test Questions and Evaluation.
- Physicians who receive a grade of 70% or better on the Post-Activity Test Questions and who complete the Evaluation will receive a CME Certificate.
- All other participants who receive a grade of 70% or better on the Post-Activity Test Questions and who complete the Evaluation will receive a Certificate of Participation.
CME Inquiries/Special Needs
Provided by AcademicCME